Tackling heterogeneity in treatment-resistant breast cancer using a broad-spectrum therapeutic approach

Area of Science:

• Oncology
• Cancer Research
• Translational Medicine

Background:

• Tumor heterogeneity is a significant challenge in treating advanced breast cancers.
• Therapeutic resistance often arises from the complex, heterogeneous nature of tumors.
• Current treatments may be limited by focusing on individual molecular targets.

Purpose of the Study:

• To identify novel therapeutic strategies addressing tumor heterogeneity and therapeutic resistance in advanced breast cancers.
• To uncover drug combinations targeting the "hallmarks of cancer" rather than single gene products.
• To leverage molecular profiling for personalized treatment approaches.

Main Methods:

• A taskforce of 180 cancer researchers conducted the Halifax project.
• Molecular profiling was used to identify key targets associated with each hallmark of cancer.
• Existing therapeutic agents, including natural health products and repurposed drugs, were evaluated for efficacy and toxicity.

Main Results:

• Key targets responsible for the hallmarks of cancer were identified.
• Combinations of therapeutics were proposed to address these targets.
• Natural health products and repurposed pharmaceuticals emerged as potential treatment agents.

Conclusions:

• Combining molecular profiling with therapeutics targeting cancer hallmarks can address tumor heterogeneity.
• This approach offers a promising strategy for overcoming therapeutic resistance in advanced breast cancers.
• The Halifax project provides a framework for developing more effective cancer treatments.